Radu Mihai1, Gregory P Sadler. 1. Department of Endocrine Surgery, level 2, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK. radumihai@doctors.org.uk
Abstract
BACKGROUND: Parathyroidectomy for primary hyperparathyroidism (PHPT) is expected to trigger an improvement in the quality of life. This has been demonstrated previously by using the SF-36 questionnaire, whose interpretation is difficult in routine clinical practice. As an alternative, the 13-item questionnaire developed by Pasieka et al. can be used to assess the severity of symptoms on a visual analogue from which a parathyroid assessment of symptoms score (PAS) can be calculated. The purpose of this study was to correlate results of these two assessment tools. METHODS: Prospective case-series study recruiting consecutive unselected patients who underwent successful parathyroidectomy for PHPT. SF-36(v2) and Pasieka's questionnaires were collected before parathyroidectomy and at 3, 6, and 12 months postoperatively. RESULTS: Between November 2005 and December 2006, 101 patients were diagnosed with PHPT (30 men; aged 18-89 years). Preoperative PAS ranged 0-1040 and did not correlate with the severity of hypercalcemia (2.91+/-0.25; range, 2.56-3.4 mmol/l). Scores from the SF-36 questionnaire were under the 50th percentile for the normal population in three domains (vitality, emotional role, and physical role). Minimally invasive parathyroidectomy was performed in 69 patients and bilateral cervical exploration in 32 patients. All were found to have a single parathyroid adenoma and were normocalcemic at 3-12 months after parathyroidectomy. At follow-up, there was a significant reduction of PAS from 460+/-257 preoperatively to 254+/-234 at 3 months postoperatively (n=72), to 245+/-215 at 6 months (n=50), and 249+/-212 at 12 months (n=63) (p<0.05, Student's t-test). There was a significant and persistent improvement in five domains of SF-36 questionnaire: bodily pain, general health, vitality, social functioning and mental health. Overall analysis of 244 assessments using both questionnaires demonstrated a negative correlation between increasing PAS and decreasing mental component scores and physical component scores of the SF-36 assessment (r2=0.372 and 0.301, respectively). CONCLUSIONS: Pasieka's parathyroid assessment of symptom scores (PAS) correlate with SF-36 questionnaire scores. Because PAS allows easier and faster analysis, we advocate that Pasieka's questionnaire should be integrated into the assessment of patients with PHPT as a reliable tool to identify symptomatic changes that correlate with improved quality of life.
BACKGROUND: Parathyroidectomy for primary hyperparathyroidism (PHPT) is expected to trigger an improvement in the quality of life. This has been demonstrated previously by using the SF-36 questionnaire, whose interpretation is difficult in routine clinical practice. As an alternative, the 13-item questionnaire developed by Pasieka et al. can be used to assess the severity of symptoms on a visual analogue from which a parathyroid assessment of symptoms score (PAS) can be calculated. The purpose of this study was to correlate results of these two assessment tools. METHODS: Prospective case-series study recruiting consecutive unselected patients who underwent successful parathyroidectomy for PHPT. SF-36(v2) and Pasieka's questionnaires were collected before parathyroidectomy and at 3, 6, and 12 months postoperatively. RESULTS: Between November 2005 and December 2006, 101 patients were diagnosed with PHPT (30 men; aged 18-89 years). Preoperative PAS ranged 0-1040 and did not correlate with the severity of hypercalcemia (2.91+/-0.25; range, 2.56-3.4 mmol/l). Scores from the SF-36 questionnaire were under the 50th percentile for the normal population in three domains (vitality, emotional role, and physical role). Minimally invasive parathyroidectomy was performed in 69 patients and bilateral cervical exploration in 32 patients. All were found to have a single parathyroid adenoma and were normocalcemic at 3-12 months after parathyroidectomy. At follow-up, there was a significant reduction of PAS from 460+/-257 preoperatively to 254+/-234 at 3 months postoperatively (n=72), to 245+/-215 at 6 months (n=50), and 249+/-212 at 12 months (n=63) (p<0.05, Student's t-test). There was a significant and persistent improvement in five domains of SF-36 questionnaire: bodily pain, general health, vitality, social functioning and mental health. Overall analysis of 244 assessments using both questionnaires demonstrated a negative correlation between increasing PAS and decreasing mental component scores and physical component scores of the SF-36 assessment (r2=0.372 and 0.301, respectively). CONCLUSIONS: Pasieka's parathyroid assessment of symptom scores (PAS) correlate with SF-36 questionnaire scores. Because PAS allows easier and faster analysis, we advocate that Pasieka's questionnaire should be integrated into the assessment of patients with PHPT as a reliable tool to identify symptomatic changes that correlate with improved quality of life.
Authors: John P Bilezikian; John T Potts; Ghada El-Hajj Fuleihan; Michael Kleerekoper; Robert Neer; Munro Peacock; Jonas Rastad; Shonni J Silverberg; Robert Udelsman; Samuel A Wells Journal: J Bone Miner Res Date: 2002-11 Impact factor: 6.741
Authors: Laura H Coker; Kashemi Rorie; Larry Cantley; Kimberly Kirkland; David Stump; Nicole Burbank; Terry Tembreull; Jeff Williamson; Nancy Perrier Journal: Ann Surg Date: 2005-11 Impact factor: 12.969
Authors: G B Talpos; H G Bone; M Kleerekoper; E R Phillips; M Alam; M Honasoge; G W Divine; D S Rao Journal: Surgery Date: 2000-12 Impact factor: 3.982
Authors: Janice L Pasieka; Louise L Parsons; Michael J Demeure; Stuart Wilson; Peter Malycha; Jean Jones; Beth Krzywda Journal: World J Surg Date: 2002-05-21 Impact factor: 3.352
Authors: Monica S Eigelberger; W Keat Cheah; Philip H G Ituarte; Leanne Streja; Quan-Yang Duh; Orlo H Clark Journal: Ann Surg Date: 2004-04 Impact factor: 12.969
Authors: Raghunandan Venkat; Guennadi Kouniavsky; Ralph P Tufano; Eric B Schneider; Alan P B Dackiw; Martha A Zeiger Journal: World J Surg Date: 2012-01 Impact factor: 3.352
Authors: Manju Chandran; Lydia Tan Li Yeh; Mechteld C de Jong; John P Bilezikian; Rajeev Parameswaran Journal: Rev Endocr Metab Disord Date: 2022-08-22 Impact factor: 9.306
Authors: N Singh Ospina; S Maraka; R Rodriguez-Gutierrez; A E Espinosa de Ycaza; S Jasim; M Gionfriddo; A Castaneda-Guarderas; J P Brito; A Al Nofal; P Erwin; R Wermers; V Montori Journal: Osteoporos Int Date: 2016-08-25 Impact factor: 4.507
Authors: Sara E Murray; Priya R Pathak; David S Pontes; David F Schneider; Sarah C Schaefer; Herbert Chen; Rebecca S Sippel Journal: Surgery Date: 2013-10-04 Impact factor: 3.982
Authors: Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian Journal: J Clin Endocrinol Metab Date: 2014-08-27 Impact factor: 5.958
Authors: Susan M Webb; Manel Puig-Domingo; Carles Villabona; Manuel Muñoz-Torres; Jordi Farrerons; Xavier Badia Journal: Health Qual Life Outcomes Date: 2013-06-18 Impact factor: 3.186